Psychopharmacology of the negative symptoms: Current status and prospects for progress

European Neuropsychopharmacology

Volumn 24, Issue 5, 2014, Pages 788-799

  Davis, Michael C ^a,b   Horan, William P ^a   Marder, Stephen R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha 7 nicotinic receptor; Clinical trials; Glycine transporter 1 inhibitor; Negative symptoms; Nmda receptor; Psychopharmacology; Schizophrenia

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ABT 107; ABT 126; AMISULPRIDE; ANTIDEPRESSANT AGENT; ASENAPINE; AZD 0328; BITOPERTIN; BRADANICLINE; BUNGAROTOXIN RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DEXTRO SERINE; ENCENICLINE; FLUPHENAZINE; GLYCINE TRANSPORTER 1; HALOPERIDOL; HORMONE; LISDEXAMFETAMINE; MEM 3454; NEUROLEPTIC AGENT; NICOTINIC AGENT; NORCLOZAPINE; OLANZAPINE; OXYTOCIN; PARTIAL AGONIST; PSYCHOSTIMULANT AGENT; RISPERIDONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL TRIAL (TOPIC); HUMAN; METHODOLOGY; NEGATIVE SYNDROME; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR BINDING; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; TREATMENT DURATION; PATHOPHYSIOLOGY; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84899857171     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.10.010     Document Type: Article

References (103)

1. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist: Rev. J. Bringing Neurobiol., Neurol. Psychiatry 2003, 9:404-416.
2. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39:784-788.
3. Asenjo Lobos, C., Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Leucht, S., 2010. Clozapine Versus Other Atypical Antipsychotics for Schizophrenia. Cochrane Database Syst. Rev., CD006633.
4. Axelrod B.N., Goldman R.S., Alphs L.D. Validation of the 16-item negative symptom assessment. J. Psychiatr. Res. 1993, 27:253-258.
5. Begemann M.J., Dekker C.F., van Lunenburg M., Sommer I.E. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr. Res. 2012, 141:179-184.
6. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013, 34:167-177.
7. Blanchard J.J., Kring A.M., Horan W.P., Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr. Bull. 2011, 37:291-299.
8. Bobo W.V., Woodward N.D., Sim M.Y., Jayathilake K., Meltzer H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr. Res. 2011, 130:106-113.
9. Bradley A.J., Dinan T.G. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J. Psychopharmacol. 2010, 24:91-118.
10. Brunelin J., Mondino M., Gassab L., Haesebaert F., Gaha L., Suaud-Chagny M.F., Saoud M., Mechri A., Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am. J. Psychiatry 2012, 169:719-724.
11. Buchanan M.D.R., Javitt M.D.P.D.D., Marder M.D.S., Schooler P.D.N., Gold P.D.J., McMahon P.D.R., Heresco-Levy M.D.U., Carpenter M.D.W. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164:1593-1602.
12. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
13. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 1998, 155:751-760.
14. Carpenter W.T., Heinrichs D.W., Alphs L.D. Treatment of negative symptoms. Schizophr. Bull. 1985, 11:440-452.
15. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145:578-583.
16. Chaudhry I.B., Hallak J., Husain N., Minhas F., Stirling J., Richardson P., Dursun S., Dunn G., Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26:1185-1193.
17. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97:1611-1626.
18. Cohen J. A power primer. Psychol. Bull. 1992, 112:155.
19. de Bartolomeis A., Sarappa C., Magara S., Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur. J. Pharmacol. 2012, 682:1-11.
20. Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012, 26:391-401.
21. Dlabac-de Lange J.J., Knegtering R., Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J. Clin. Psychiatry 2010, 71:411-418.
22. Elias, A., Kumar, A., 2007. Testosterone for Schizophrenia. Cochrane Database Syst. Rev., CD006197.
23. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr. Bull. 2006, 32:234-237.
24. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68:678-680.
25. Ferraris D.V., Tsukamoto T. Recent advances in the discovery of d-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr. Pharm. Des. 2011, 17:103-111.
26. Fett A.K., Viechtbauer W., Dominguez M.D., Penn D.L., van Os J., Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 2011, 35:573-588.
27. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165:1040-1047.
28. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 321:1371-1376.
29. Gerlach J. Atypical antipsychotics: an inspiring but confusing concept. Psychopharmacology 2000, 148:1-2.
30. Gitlin M., Frye M.A. Maintenance therapies in bipolar disorders. Bipolar Disord. 2012, 14(Suppl 2):51-65.
31. Goff D.C. D-Cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophr. Bull. 2012, 38:936-941.
32. Grant K.M., LeVan T.D., Wells S.M., Li M., Stoltenberg S.F., Gendelman H.E., Carlo G., Bevins R.A. Methamphetamine-associated psychosis. J. Neuroimmune Pharmacol.: Off. J. Soc. Neuroimmune Pharmacol. 2012, 7:113-139.
33. Guest P.C., Martins-de-Souza D., Vanattou-Saifoudine N., Harris L.W., Bahn S. Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia. Int. Rev. Neurobiol. 2011, 101:145-168.
34. Hahn C.G., Gyulai L., Baldassano C.F., Lenox R.H. The current understanding of lamotrigine as a mood stabilizer. J. Clin. Psychiatry 2004, 65:791-804.
35. Hartling L., Abou-Setta A.M., Dursun S., Mousavi S.S., Pasichnyk D., Newton A.S. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann. Intern. Med. 2012, 157:498-511.
36. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:367-377.
37. Hayes E., Gavrilidis E., Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophr. Res. Treat. 2012, 2012:540273.
38. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 2009, 30:548-557.
39. Herman E.J., Bubser M., Conn P.J., Jones C.K. Metabotropic glutamate receptors for new treatments in schizophrenia. Handb. Exp. Pharmacol. 2012, 213:297-365.
40. Hilt, D., Meltzer, H., Gawry, M., Ward, S., Dgetluck, N., Bhuvaneswaran, C., Koenig, G., Palfreyman, M., 2011. EVP-6124, An Alpha-7 Nicotinic Partial Agonist, produces Positive Effects on Cognition, Clinical Function, and Negative Symptoms in Patients with Chronic Schizophrenia on Stable Antipsychotic Therapy, ACNP 50th Annual Meeting, Waikaloa, HI.
41. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., Höschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
42. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. Drug Discov. 2009, 8:523-524.
43. Ishizuka T., Murotani T., Yamatodani A. Action of modafinil through histaminergic and orexinergic neurons. Vitam. Horm. 2012, 89:259-278.
44. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
45. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2012, 37:16-42.
46. Joober R., Boksa P. Clozapine: a distinct, poorly understood and under-used molecule. J. Psychiatry Neurosci.: JPN 2010, 35:147-149.
47. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
48. Kane J.M., Yang R., Youakim J.M. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res. 2012, 135:116-122.
49. Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., Lizardi-Ortiz J.E., Markx S., Lieberman J.A., Javitch J.A. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci. 2010, 31:381-390.
50. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
51. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4:287-293.
52. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
53. Kulkarni J., de Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Burger H. Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125:278-283.
54. Kulkarni J., Hayes E., Gavrilidis E. Hormones and schizophrenia. Curr. Opin. Psychiatry 2012, 25:89-95.
55. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37:255-256.
56. Lee M.R., Wehring H.J., McMahon R.P., Linthicum J., Cascella N., Liu F., Bellack A., Buchanan R.W., Strauss G.P., Contoreggi C., Kelly D.L. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study. Schizophr. Res. 2013, 145:110-115.
57. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
58. Levine S.Z., Leucht S. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 2012, 22:812-817.
59. Levine S.Z., Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr. Res. 2013, 145:125-127.
60. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., Fennig S., Treves I., Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 2010, 71:138-149.
61. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2013, 38:968-975.
62. Lieberman J.A., Papadakis K., Csernansky J., Litman R., Volavka J., Jia X.D., Gage A., Group M.-M.-S. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34:1322-1329.
63. Lindenmayer J.P., Nasrallah H., Pucci M., James S., Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr. Res. 2013, 147:241-252.
64. Marder S.R., Daniel D.G., Alphs L., Awad A.G., Keefe R.S. Methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37:250-254.
65. Martin-Facklam M., Pizzagalli F., Zhou Y., Ostrowitzki S., Raymont V., Brasic J.R., Parkar N., Umbricht D., Dannals R.F., Goldwater R., Wong D.F. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2013, 38:504-512.
66. Marx C.E., Bradford D.W., Hamer R.M., Naylor J.C., Allen T.B., Lieberman J.A., Strauss J.L., Kilts J.D. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011, 191:78-90.
67. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., Investigators C. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
68. Meltzer H.Y., Sommers A.A., Luchins D.J. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 1986, 6:329-338.
69. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 2011, 12:524-538.
70. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., Hosseini S.M., Tajdini M., Ghaleiha A., Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27:57-65.
71. Moller H.J. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur. Arch. Psychiatry. Clin. Neurosci. 1999, 249(Suppl 4):99-107.
72. Mortimer A.M. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr. Dis. Treat. 2009, 5:267-277.
73. Murphy B.P., Chung Y.C., Park T.W., McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr. Res. 2006, 88:5-25.
74. Naheed M., Green B. Focus on clozapine. Curr. Med. Res. Opin. 2001, 17:223-229.
75. Nolte, S., Wong, D., Lachford, G., 2004. Amphetamines for Schizophrenia. Cochrane Database Syst. Rev., CD004964.
76. Papouin T., Ladepeche L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L., Pollegioni L., Mothet J.P., Oliet S.H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
77. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
78. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68:705-710.
79. Potkin S.G., Phiri P., Szegedi A., Zhao J., Alphs L., Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr. Res. 2013, 150:442-449.
80. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
81. Rummel C., Kissling W., Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr. Res. 2005, 80:85-97.
82. Sagud M., Mihaljevic-Peles A., Muck-Seler D., Pivac N., Vuksan-Cusa B., Brataljenovic T., Jakovljevic M. Smoking and schizophrenia. Psychiatr. Danubina 2009, 21:371-375.
83. Sasayama D., Hattori K., Teraishi T., Hori H., Ota M., Yoshida S., Arima K., Higuchi T., Amano N., Kunugi H. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr. Res. 2012, 139:201-206.
84. Schmitt K.C., Reith M.E. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci. 2010, 1187:316-340.
85. Shajahan P.M., Glabus M.F., Steele J.D., Doris A.B., Anderson K., Jenkins J.A., Gooding P.A., Ebmeier K.P. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and functional connectivity, but does not impair cognition in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:945-954.
86. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
87. Singh, J., Kour, K., Jayaram, M.B., 2012. Acetylcholinesterase Inhibitors for Schizophrenia. Cochrane Database Syst. Rev. 1, CD007967.
88. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
89. Singh S.P., Singh V., Kar N., Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry: J. Ment. Sci. 2010, 197:174-179.
90. Speller J.C., Barnes T.R., Curson D.A., Pantelis C., Alberts J.L. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br. J. Psychiatry: J. Ment. Sci. 1997, 171:564-568.
91. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
92. Stauffer V.L., Millen B.A., Andersen S., Kinon B.J., Lagrandeur L., Lindenmayer J.P., Gomez J.C. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr. Res. 2013, 150:434-441.
93. Storosum J.G., Elferink A.J., van Zwieten B.J., van Strik R., Hoogendijk W.J., Broekmans A.W. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?. Schizophr. Bull. 2002, 28:193-201.
94. Swerdlow N.R. Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2012, 37:310-311.
95. Tiihonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2009, 109:10-14.
96. Tollefson G.D., Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 1997, 154:466-474.
97. Tuominen, H.J., Tiihonen, J., Wahlbeck, K., 2006. Glutamatergic Drugs for Schizophrenia. Cochrane Database Syst. Rev., CD003730.
98. Umbricht, D., Yoo, K., Youssef, E., Dorflinger, E., Martin-Facklam, M., Bausch, A., Arrowsmith, R., Alberati, D., Marder, S.R., Santarelli, L., 2010. Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: Positive Results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia. ACNP 49th Annual Meeting, Miami Beach, FL.
99. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1552-1557.
100. Van Putten T., Marder S.R. Behavioral toxicity of antipsychotic drugs. J. Clin. Psychiatry 1987, 48(Suppl):13-19.
101. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113:189-199.
102. Wood S.J., Yung A.R., McGorry P.D., Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol. Psychiatry 2011, 70:619-625.
103. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., Prisinzano T.E., Baumann M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther. 2009, 329:738-746.